These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17970894)

  • 1. The use of i.v. IG therapy in dermatology.
    Fernandez AP; Kerdel FA
    Dermatol Ther; 2007; 20(4):288-305. PubMed ID: 17970894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin: use in dermatology.
    Mydlarski PR; Mittmann N; Shear NH
    Skin Therapy Lett; 2004 May; 9(5):1-6. PubMed ID: 15146260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravenous immunoglobulins in dermatology].
    Nydegger U; Hunziker T
    Ann Dermatol Venereol; 2002; 129(8-9):1078-81. PubMed ID: 12442118
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 May; 41(5):812-23. PubMed ID: 17440006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology.
    Prins C; Gelfand EW; French LE
    Acta Derm Venereol; 2007; 87(3):206-18. PubMed ID: 17533485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.
    Rütter A; Luger TA
    J Am Acad Dermatol; 2001 Jun; 44(6):1010-24. PubMed ID: 11369915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Toxic epidermal necrolysis. Therapy in ICU with intravenous immunoglobulins in a case].
    Andresen M; Boghero Y; Molgó M; Dougnao A; Díaz O
    Rev Med Chil; 2000 Dec; 128(12):1343-8. PubMed ID: 11227243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
    Dalakas MC
    Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2).
    Smith DI; Swamy PM; Heffernan MP
    J Am Acad Dermatol; 2007 Jan; 56(1):e1-54. PubMed ID: 17190617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses.
    Michael D; Grando SA
    Curr Dir Autoimmun; 2008; 10():333-43. PubMed ID: 18460894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of high-dose immunoglobulins in dermatology.
    Enk A; Fierlbeck G; French L; Hertl M; Messer G; Meurer M; Steinbrink K; Stingl G; Volc-Platzer B; Zillikens D
    J Dtsch Dermatol Ges; 2009 Sep; 7(9):806-812. PubMed ID: 19624804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin treatment: Where do dermatologists stand?
    Emre S
    Dermatol Ther; 2019 May; 32(3):e12854. PubMed ID: 30756448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis.
    Paquet P; Kaveri S; Jacob E; Pirson J; Quatresooz P; Piérard GE
    Exp Dermatol; 2006 May; 15(5):381-6. PubMed ID: 16630079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of intravenous immunoglobulin for treatment of dermatological conditions in Australia: A review.
    Smith SD; Dennington PM; Cooper A
    Australas J Dermatol; 2010 Nov; 51(4):227-37. PubMed ID: 21198517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin.
    Simeone F; Rubio ER
    J La State Med Soc; 2003; 155(5):266-9. PubMed ID: 14748489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IVIG for the treatment of toxic epidermal necrolysis.
    Mittmann N; Chan BC; Knowles S; Shear NH
    Skin Therapy Lett; 2007 Feb; 12(1):7-9. PubMed ID: 17361314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous IgG: biological modulating molecules.
    Luzi G; Bongiorno F; Paparo Barbaro S; Bruno G
    J Biol Regul Homeost Agents; 2009; 23(1):1-9. PubMed ID: 19321040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic epidermal necrolysis treated with intravenous immunoglobulin and granulocyte colony-stimulating factor.
    Kalyoncu M; Cimsit G; Cakir M; Okten A
    Indian Pediatr; 2004 Apr; 41(4):392-5. PubMed ID: 15123870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin and autoimmune disease.
    El-Shanawany T; Jolles S
    Ann N Y Acad Sci; 2007 Sep; 1110():507-15. PubMed ID: 17911466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.